<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02791750</url>
  </required_header>
  <id_info>
    <org_study_id>ICL OBS 02</org_study_id>
    <nct_id>NCT02791750</nct_id>
  </id_info>
  <brief_title>5 Years Follow-up With Adjuvant Therapy for Women With Breast Invasive Carcinoma</brief_title>
  <acronym>HACAMI</acronym>
  <official_title>5 Years Follow-up in the Lorraine Institute of Oncology With Adjuvant Therapy for Women With Breast Invasive Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-persistence to adjuvant hormonal therapy for breast cancer at 5 years decrease its
      efficacy. The objective of this study is to know the women experience (persistence, treatment
      changes, quality of life) and its determinants, in a french population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2016</start_date>
  <completion_date type="Actual">June 3, 2017</completion_date>
  <primary_completion_date type="Actual">June 3, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Factors associated with persistence to hormone therapy for breast cancer</measure>
    <time_frame>1 day</time_frame>
    <description>Women will be classed as persistent if they don't discontinue or abandon hormone therapy during the 5 years after the introduction of the medication. The information will be recorded thanks to a self-questionnary fulfilled the inclusion day.
The baseline characteristics will be compared between persistent women and non-persistent women.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the quality of life</measure>
    <time_frame>1 day</time_frame>
    <description>Quality of life between patients who continued hormone therapy for 5 years and patients who discontinued treatment early will be searched for using the questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of women with a change in their treatment</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of women who have changed treatment within 5 years following the placing on hormone therapy and reasons for the change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause of treatment discontinuation</measure>
    <time_frame>1 day</time_frame>
    <description>In the subgroup of women who stopped hormone therapy within 5 years following the hormone therapy, determination of the treatment discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continued homonotherapy</measure>
    <time_frame>1 day</time_frame>
    <description>In the subgroup of women who have been treated with hormone therapy for 5 years, determine the proportion of women not opposed to the continuation of hormone therapy beyond 5 years</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <description>Patients followed for a medical consultation in the Institut de Cancérologie de Lorraine at 5 years of the beginning of an adjuvant hormonal therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnary of quality of life</intervention_name>
    <arm_group_label>Observational</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients following-up in the Lorraine Institute of Oncology at 5 years of the beginning of
        an adjuvant hormonal therapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients following-up in the Lorraine Institute of Oncology at 5 years of the
             beginning of an adjuvant hormonal therapy

          -  Women with breast invasive carcinoma positive-RH and indication of adjuvant hormonal
             therapy

          -  Adult patients

          -  Being capable and agree to follow the study procedure

          -  Patients informed and non-opposed

          -  Covered by social security

        Exclusion Criteria:

          -  History of other cancer except basal cell carcinoma

          -  Patients with breast invasive carcinoma negative-RH

          -  Synchronous metastases

          -  Relapsed

          -  Previous adjuvant hormonal therapy

          -  Men

          -  Patients with guardianship
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LESUR ANNE, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre lès Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>June 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hormone replacement therapy</keyword>
  <keyword>breast cancer</keyword>
  <keyword>follow up</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

